Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084   20/03/2026
7,120 USD (-16,92%)
(-16,92%)   20/03/2026

19 maart 2026 · Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods · Persbericht

3 maart 2026 · Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years · Persbericht

26 februari 2026 · Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference · Persbericht

25 februari 2026 · Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

20 februari 2026 · Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation · Persbericht

11 februari 2026 · Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

5 februari 2026 · Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 · Persbericht

8 januari 2026 · Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder · Persbericht

31 december 2025 · Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness · Persbericht

15 december 2025 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

11 december 2025 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

4 december 2025 · FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness · Persbericht

28 november 2025 · Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness · Persbericht

18 november 2025 · Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting · Persbericht

5 november 2025 · Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference · Persbericht

29 oktober 2025 · Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results · Persbericht

22 oktober 2025 · Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 · Persbericht

8 oktober 2025 · Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena · Persbericht

1 oktober 2025 · Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration · Persbericht

25 september 2025 · Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" · Persbericht

Mijn selecties